HSCS (HeartSciences) Common Stock : $0.00 Mil (As of Jan. 2025)

View and export this data going back to 2022. Start your Free Trial

What is HeartSciences Common Stock?

HeartSciences's quarterly common stock stayed the same from Jul. 2024 ($0.00 Mil) to Oct. 2024 ($0.00 Mil) and stayed the same from Oct. 2024 ($0.00 Mil) to Jan. 2025 ($0.00 Mil).

HeartSciences's annual common stock declined from Apr. 2022 ($0.00 Mil) to Apr. 2023 ($0.00 Mil) but then increased from Apr. 2023 ($0.00 Mil) to Apr. 2024 ($0.00 Mil).

HeartSciences Common Stock Historical Data

The historical data trend for HeartSciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartSciences Common Stock Chart

HeartSciences Annual Data

Trend

Apr20

Apr21

Apr22

Apr23

Apr24

Common Stock

HeartSciences Quarterly Data
	Apr20	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Common Stock	Get a 7-Day Free Trial												0.06	-	-	-	-

HeartSciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

HeartSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeartSciences Inc (NAS:HSCS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

550 Reserve Street, Suite 360, Southlake, TX, USA, 76092

Website

https://www.heartsciences.com

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

Executives

David R. Wells	director	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent	director	750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz	director, officer: See Remarks	3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson	officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson	director, officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092